Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Examining transcriptional changes to DNA replication and repair factors over uveal melanoma subtypes

Author: Melanie Kucherlapati

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Uncontrolled replication is a process common to all cancers facilitated by the summation of changes accumulated as tumors progress. The aim of this study was to examine small groups of genes with known biology in replication and repair at the transcriptional and genomic levels, correlating alterations with survival in uveal melanoma tumor progression. Selected components of Pre-Replication, Pre-Initiation, and Replisome Complexes, DNA Damage Response and Mismatch Repair have been observed.

Methods

Two groups have been generated for selected genes above and below the average alteration level and compared for expression and survival across The Cancer Genome Atlas uveal melanoma subtypes. Significant differences in expression between subtypes monosomic or disomic for chromosome 3 have been identified by Fisher’s exact test. Kaplan Meier survival distribution based on disease specific survival has been compared by Log-rank test.

Results

Genes with significant alteration include MCM2, MCM4, MCM5, CDC45, MCM10, CIZ1, PCNA, FEN1, LIG1, POLD1, POLE, HUS1, CHECK1, ATRIP, MLH3, and MSH6. Exon 4 skipping in CIZ1 previously identified as a cancer variant, and reportedly used as an early serum biomarker in lung cancer was found. Mismatch Repair protein MLH3 was found to have splicing variations with deletions to both Exon 5 and Exon 7 simultaneously. PCNA, FEN1, and LIG1 had increased relative expression levels not due to mutation or to copy number variation.

Conclusion

The current study proposes changes in relative and differential expression to replication and repair genes that support the concept their products are causally involved in uveal melanoma. Specific avenues for early biomarker identification and therapeutic approach are suggested.
Literature
1.
Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32(2):204–20 e15. PubMed PMID: 28810145CrossRefPubMedPubMedCentral
2.
Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5. PubMed PMID: 21704381CrossRefPubMed
3.
Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279–89. PubMed PMID: 28203054. Pubmed Central PMCID: 5298817CrossRefPubMedPubMedCentral
4.
Bournique E, Dall'Osto M, Hoffmann JS, Bergoglio V. Role of specialized DNA polymerases in the limitation of replicative stress and DNA damage transmission. Mutat Res. 2017; PubMed PMID: 28843435.
5.
Royer-Bertrand B, Torsello M, Rimoldi D, El Zaoui I, Cisarova K, Pescini-Gobert R, et al. Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. Am J Hum Genet. 2016;99(5):1190–8. PubMed PMID: 27745836. Pubmed Central PMCID: 5097942CrossRefPubMedPubMedCentral
6.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. PubMed PMID: 23550210. Pubmed Central PMCID: 4160307CrossRefPubMedPubMedCentral
7.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. PubMed PMID: 22588877. Pubmed Central PMCID: 3956037CrossRefPubMed
8.
9.
10.
Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013 Mar;14(2):178–92. PubMed PMID: 22517427. Pubmed Central PMCID: 3603213
11.
Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–6. PubMed PMID: 21221095. Pubmed Central PMCID: 3346182CrossRefPubMedPubMedCentral
12.
13.
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V, Cancer Genome Atlas Research, Network, Hu H. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell.2018;173(2):400–16. PMCID: 6066282.
14.
15.
Coverley D, Marr J, Ainscough J. Ciz1 promotes mammalian DNA replication. J Cell Sci. 2005;118(Pt 1):101–12. PubMed PMID: 15585571CrossRefPubMed
16.
Ainscough JF, Rahman FA, Sercombe H, Sedo A, Gerlach B, Coverley D. C-terminal domains deliver the DNA replication factor Ciz1 to the nuclear matrix. J Cell Sci. 2007;120(Pt 1):115–24. PubMed PMID: 17182902PubMed
17.
Copeland NA, Sercombe HE, Ainscough JF, Coverley D. Ciz1 cooperates with cyclin-A-CDK2 to activate mammalian DNA replication in vitro. J Cell Sci. 2010;123(Pt 7):1108–15. PubMed PMID: 20215406. Pubmed Central PMCID: 2844319CrossRefPubMedPubMedCentral
18.
Munkley J, Copeland NA, Moignard V, Knight JR, Greaves E, Ramsbottom SA, et al. Cyclin E is recruited to the nuclear matrix during differentiation, but is not recruited in cancer cells. Nucleic Acids Res. 2011;39(7):2671–7. PubMed PMID: 21109536. Pubmed Central PMCID: 3074132CrossRefPubMed
19.
Greaves EA, Copeland NA, Coverley D, Ainscough JF. Cancer-associated variant expression and interaction of CIZ1 with cyclin A1 in differentiating male germ cells. J Cell Sci. 2012;125(Pt 10):2466–77. PubMed PMID: 22366453CrossRefPubMed
20.
Pauzaite T, Thacker U, Tollitt J, Copeland NA. Emerging roles for Ciz1 in cell cycle regulation and as a driver of tumorigenesis. Biomol Ther. 2016;27:7(1). PubMed PMID: 28036012. Pubmed Central PMCID: 5372713
21.
Rahman F, Ainscough JF, Copeland N, Coverley D. Cancer-associated missplicing of exon 4 influences the subnuclear distribution of the DNA replication factor CIZ1. Hum Mutat. 2007;28(10):993–1004. PubMed PMID: 17508423CrossRefPubMed
22.
Higgins G, Roper KM, Watson IJ, Blackhall FH, Rom WN, Pass HI, et al. Variant Ciz1 is a circulating biomarker for early-stage lung cancer. Proc Natl Acad Sci U S A. 2012;109(45):E3128–35. PubMed PMID: 23074256. Pubmed Central PMCID: 3494940CrossRefPubMedPubMedCentral
23.
Dobbelstein M, Sorensen CS. Exploiting replicative stress to treat cancer. Nat Rev Drug Discov. 2015;14(6):405–23. PubMed PMID: 25953507CrossRefPubMed
24.
Puigvert JC, Sanjiv K, Helleday T. Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies. FEBS J. 2016;283(2):232–45. PubMed PMID: 26507796CrossRefPubMed
25.
Riera A, Barbon M, Noguchi Y, Reuter LM, Schneider S, Speck C. From structure to mechanism-understanding initiation of DNA replication. Genes Dev. 2017;31(11):1073–88. PubMed PMID: 28717046CrossRefPubMedPubMedCentral
26.
Pruitt SC, Bailey KJ, Freeland A. Reduced Mcm2 expression results in severe stem/progenitor cell deficiency and cancer. Stem Cells. 2007;25(12):3121–32. PubMed PMID: 17717065CrossRefPubMed
27.
Shima N, Alcaraz A, Liachko I, Buske TR, Andrews CA, Munroe RJ, et al. A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nat Genet. 2007;39(1):93–8. PubMed PMID: 17143284CrossRefPubMed
28.
Kunnev D, Rusiniak ME, Kudla A, Freeland A, Cady GK, Pruitt SC. DNA damage response and tumorigenesis in Mcm2-deficient mice. Oncogene. 2010;29(25):3630–8. PubMed PMID: 20440269. Pubmed Central PMCID: 2892019CrossRefPubMedPubMedCentral
29.
Kawabata T, Luebben SW, Yamaguchi S, Ilves I, Matise I, Buske T, et al. Stalled fork rescue via dormant replication origins in unchallenged S phase promotes proper chromosome segregation and tumor suppression. Mol Cell. 2011;41(5):543–53. PubMed PMID: 21362550. Pubmed Central PMCID: 3062258CrossRefPubMedPubMedCentral
30.
Rusiniak ME, Kunnev D, Freeland A, Cady GK, Pruitt SC. Mcm2 deficiency results in short deletions allowing high resolution identification of genes contributing to lymphoblastic lymphoma. Oncogene. 2012;31(36):4034–44. PubMed PMID: 22158038. Pubmed Central PMCID: 3309111CrossRefPubMed
31.
Kunnev D, Freeland A, Qin M, Leach RW, Wang J, Shenoy RM, et al. Effect of minichromosome maintenance protein 2 deficiency on the locations of DNA replication origins. Genome Res. 2015;25(4):558–69. PubMed PMID: 25762552. Pubmed Central PMCID: 4381527CrossRefPubMedPubMedCentral
32.
Huang H, Stromme CB, Saredi G, Hodl M, Strandsby A, Gonzalez-Aguilera C, et al. A unique binding mode enables MCM2 to chaperone histones H3-H4 at replication forks. Nat Struct Mol Biol. 2015;22(8):618–26. PubMed PMID: 26167883. Pubmed Central PMCID: 4685956CrossRefPubMedPubMedCentral
33.
Ishimi Y, Komamura-Kohno Y, Arai K, Masai H. Biochemical activities associated with mouse Mcm2 protein. J Biol Chem. 2001;276(46):42744–52. PubMed PMID: 11568184CrossRefPubMed
34.
Di Paola D, Zannis-Hadjopoulos M. Comparative analysis of pre-replication complex proteins in transformed and normal cells. J Cell Biochem. 2012;113(4):1333–47. PubMed PMID: 22134836CrossRefPubMed
35.
Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Takeda K, Aburatani H, et al. Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer. Lung Cancer. 2011;72(2):229–37. PubMed PMID: 20884074CrossRefPubMed
36.
Sheu YJ, Kinney JB, Lengronne A, Pasero P, Stillman B. Domain within the helicase subunit Mcm4 integrates multiple kinase signals to control DNA replication initiation and fork progression. Proc Natl Acad Sci U S A. 2014;111(18):E1899–908. PubMed PMID: 24740181. Pubmed Central PMCID: 4020090CrossRefPubMedPubMedCentral
37.
Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD, Lynch HT, et al. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. Nat Genet. 2000;24(1):27–35. PubMed PMID: 10615123CrossRefPubMed
38.
Choe KN, Moldovan GL. Forging ahead through darkness: PCNA, still the principal conductor at the replication fork. Mol Cell. 2017;65(3):380–92. PubMed PMID: 28157503. Pubmed Central PMCID: 5302417CrossRefPubMedPubMedCentral
39.
De Biasio A, Blanco FJ. Proliferating cell nuclear antigen structure and interactions: too many partners for one dancer? Adv Protein Chem Struct Biol. 2013;91:1–36. PubMed PMID: 23790209CrossRefPubMed
40.
Boehm EM, Washington MT. R.I.P. to the PIP: PCNA-binding motif no longer considered specific: PIP motifs and other related sequences are not distinct entities and can bind multiple proteins involved in genome maintenance. BioEssays. 2016;38(11):1117–22. PubMed PMID: 27539869. Pubmed Central PMCID: 5341575CrossRefPubMedPubMedCentral
41.
Stoimenov I, Helleday T. PCNA on the crossroad of cancer. Biochem Soc Trans. 2009;37(Pt 3):605–13. PubMed PMID: 19442257CrossRefPubMed
42.
Wang SC. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014;35(4):178–86. PubMed PMID: 24655521CrossRefPubMed
43.
Smith SJ, Gu L, Phipps EA, Dobrolecki LE, Mabrey KS, Gulley P, et al. A peptide mimicking a region in proliferating cell nuclear antigen specific to key protein interactions is cytotoxic to breast cancer. Mol Pharmacol. 2015;87(2):263–76. PubMed PMID: 25480843. Pubmed Central PMCID: 4293449CrossRefPubMedPubMedCentral
44.
Gu L, Smith S, Li C, Hickey RJ, Stark JM, Fields GB, et al. A PCNA-derived cell permeable peptide selectively inhibits neuroblastoma cell growth. PLoS One. 2014;9(4):e94773. PubMed PMID: 24728180. Pubmed Central PMCID: 3984256CrossRefPubMedPubMedCentral
45.
Stillman B, Reconsidering DNA. Polymerases at the replication fork in eukaryotes. Mol Cell. 2015;59(2):139–41. PubMed PMID: 26186286. Pubmed Central PMCID: 4636199CrossRefPubMedPubMedCentral
46.
Rundle S, Bradbury A, Drew Y, Curtin NJ. Targeting the ATR-CHK1 Axis in Cancer Therapy. Cancers (Basel). 2017;9(5):41. PubMed PMID: 2844862. Pubmed Central PMCID: 5447951.
47.
Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 2003;300(5625):1542–8. PubMed PMID: 12791985CrossRefPubMed
48.
O'Connell BC, Adamson B, Lydeard JR, Sowa ME, Ciccia A, Bredemeyer AL, et al. A genome-wide camptothecin sensitivity screen identifies a mammalian MMS22L-NFKBIL2 complex required for genomic stability. Mol Cell. 2010;40(4):645–57. PubMed PMID: 21055985. Pubmed Central PMCID: 3006237CrossRefPubMedPubMedCentral
49.
Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science. 2001;294(5547):1713–6. PubMed PMID: 11721054CrossRefPubMed
50.
Cortez D, Glick G, Elledge SJ. Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci U S A. 2004;101(27):10078–83. PubMed PMID: 15210935. Pubmed Central PMCID: 454167CrossRefPubMedPubMedCentral
51.
Burrows AE, Elledge SJ. How ATR turns on: TopBP1 goes on ATRIP with ATR. Genes Dev. 2008;22(11):1416–21. PubMed PMID: 18519633. Pubmed Central PMCID: 2732414CrossRefPubMedPubMedCentral
52.
Ismail IH, Davidson R, Gagne JP, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Res. 2014;74(16):4282–94. PubMed PMID: 24894717CrossRefPubMed
53.
Yu H, Pak H, Hammond-Martel I, Ghram M, Rodrigue A, Daou S, et al. Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci U S A. 2014;111(1):285–90. PubMed PMID: 24347639. Pubmed Central PMCID: 3890818CrossRefPubMed
54.
55.
Metadata
Title
Examining transcriptional changes to DNA replication and repair factors over uveal melanoma subtypes
Author
Melanie Kucherlapati
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4705-y

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Investigation of chemotherapy-induced brain structural alterations in breast cancer patients with generalized q-sampling MRI and graph theoretical analysis

Research article

Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres

Research article

Time to diagnosis and associated costs of an outpatient vs inpatient setting in the diagnosis of lymphoma: a retrospective study of a large cohort of major lymphoma subtypes in Spain

Research article

Development of a computational promoter with highly efficient expression in tumors

Study protocol

Rationale and design of the Caloric Restriction and Exercise protection from Anthracycline Toxic Effects (CREATE) study: a 3-arm parallel group phase II randomized controlled trial in early breast cancer

Research article

Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits